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ABSTRACT
Borderline ovarian tumors are classified between benign cystadenoma and malignant cystadenocarci-
noma. They are characterized as malignant tumors by histopathological features, which make them dif-
ferent from the benign ones. These tumors are commonly diagnosed at the early disease stage. The
treatment of these tumors is surgical. The prognosis depends on the stage of disease and histopahto-
logical types. We present 10 patients operated at the Institute of Oncology Sremska Kamenica because
of malignant tumors with low malignant oncogenic potential in the period between 2000 and 2005. All
patients had surgical treatment with ex tempore diagnostics, hysterectomy and adnexectomy with total
omentectomy, or unilaterals adnexectomy. All patients had negative cytoanalytic findings of the small
pelvis. Histopathological findings are necessary to confirm the diagnosis of disease. In young patients
who had no children fertility can be preserved.
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INTRODUCTION 
A
ccording to the ovarian tumor classification, borderline ovarian tumors are classified
between benign cystadenoma and malignant cystadenocarcinoma. These tumors were
first described in 1929 by Taylor and they are characterized by special histopathological
features that make them different from the benign ones. These tumors are malignant by their
origin but their biological behavior is different from solely malignant forms. The course of a
disease is slower which makes the prognosis of the disease better for a patient. That is why
they are called the tumors of the low malignancy level or the tumors of the low malignant
potential. These tumors were recognized by the FIGO as a separate entity in 1961 and intro-
duced in the World Health Organization nomenclature in 1973. They occur in two forms: as
serous and as mucinous border line tumors by epithelial origin. The serous borderline
tumors occur much more often than the mucinous ones while the endometrial ones, clear
cell and Brener type, are very rare. Borderline ovarian tumors are not described along with
non-epithelial tumors (1). There are not many information on the risk factors of these
tumors. It is well known that women with infertility and those who have never given a birth
are more likely to become ill. Breast-feeding and previous pregnancies decrease the risk of
these tumors. The effect of birth-control pills is still controversial (1,2).
These tumors make 1%-2% of all malignant ovarian tumors. The majority of solely malig-
nant are diagnosed in progressive or even terminal disease stage when metastases appear,
while these tumors are mostly diagnosed in the first stage. The metastases very rarely
appear with these tumors as well as the relapse of the disease and they occur approxi-
mately in 15%-20% of the cases. The serous borderline tumors give metastases more often
than the mucinous one (3).
Although rare, the metastases of these tumors can usually be found on the peritoneum of
the small pelvis and the abdomen, while farther metastases have been described very
rarely. The relapse usually occurs after a long time and the latent period can last up to two
or even three decades. Due to the timely disease diagnosis and the rare occurrence of
metastases, the prognosis is very good (4,5). Borderline tumors are usually unilateral while
bilateral occurrence is very rare. For that reason, the lower stage is more common.
The tumors of the lower malignant potentials occur with younger women, between 20 and
40 years old, but they can also occur with older women, and after the menopause.
Considering the low malignancy of these tumors, the patients￿ fertility can be preserved by
conservative surgical treatment. The stages of borderline ovarian tumors are determined in
the same way as with other malignant ovarian tumors and according to the FIGO classifi-
cation, they are divided into 4 stages of the disease (6,7). The clinical picture of these
tumors is usually dominated by unilateral tumor mass, which can be large and accompa-
nied with compressive symptomatology, pain, stomach swell, irregular vaginal hemorrhage
or the disease can be asymptomatic. The diagnosis of these tumors along with the clinical
examination, US findings and NMR is not specific. The definite diagnosis is made by histop-
tahological confirmation taking into consideration certain parameters: excessive cell strati-
fication, the existence of nuclear atypia, mitotic activity and without the ovarian stroma inva-
sion (8). The treatment of these tumors is solely surgical. According to the treatment pro-
tocol at more progressive stages of the disease, a hysterectomy must be done with the
adnexectomy on both sides and the total omentectomy (9).
At the first stage of the disease, a conservative surgical treatment can be done in order to
preserve fertility. The treatment includes the removal of the ill ovary with ex tempore diag-
nostics and the biopsy of the other ovary and the omentum. For the purpose of the correct
staging, the cytoanalysis of the small pelvis or ascites if present. The attitudes toward the
use of chemotherapy still vary, but progressive disease or a large tumor mass is the indi-
cation for further treatment.
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type. The risk of metastases and disease relapse is smaller with patients younger than 40
especially if they are in the first disease stage of the mucinous tumor. The patients with high
risk are those who are over 70 with the serous type and the third disease stage (10).
CASE REPORT
The work describes 10 patients operated at the Institute of Oncology Sremska Kamenica
because of the malignant tumors of the low oncogenic potential in the period between 2000
and 2005. Before the operation and after the clinical examination all patients went through
additional diagnostics: US of the small pelvis and the upper abdomen, the serum level of
tumor marker Ca125, X-ray of the chest and laboratory analysis. 
The average age of the operated patients is 50. The youngest patient was 38 and the old-
est one was 67. Five of them were in the postmenopausal age. Five patients had the bor-
derline tumors on both ovaries while the other five had unilaterally localized tumors. All the
patients had normal US findings of the upper abdomen as well as normal X-ray of the chest
and other pre-operative laboratory findings. The level of the associated tumor antigen
Ca125 showed increased values but not over 60.
Five patients had hysterectomy with adnexectomy on both sides and total omentectomy.
Three patients had hysterectomy with adnexectomy. One patient had hysterectomy with
unilateral adnexectomy while the other one had unilateral adnexectomy with the biopsy of
the other ovary. Ex tempore diagnostics was done intraoperatively with all operated patients
and that determined the further course of the treatment. All of them had the negative cyto-
analytic findings of the small pelvis. In all patients, histolpathological finding was serous
borderline ovarian carcinoma. In all cases staging of disease was I a (Figure 1). Due to the
large tumor mass, four patients were postoperatively given the chemotherapy according to
the carboplatin and Endoxan protocol in specific doses during three series.
DISCUSSION
Borderline ovarian tumors are very rare primary ovarian tumors, which can occur with
women of different age. These tumors are mostly found at the early disease stage and they
very rarely give metastases. The choice of operative treatment depends on the disease
stage and patient￿s age. The third condition can be patient￿s wish to preserve her fertility. In
our case, with all postmenopausal women and with those who had borderline ovarian
tumors on both sides we did hysterectomy with adnexectomy and total omentectomy (11).
The patients with unilateral tumors had hysterectomy with adnexectomy on both sides while
one patient who had not had children had adnexectomy with the biopsy of the other ovary
with the purpose of fertility preservation (12).
The clinical examination of a patient within pre-operative treatment and additional diagnos-
tics - US of the small pelvis, CT of the abdomen and NMR, are not sufficient to create the
complete picture of the disease. Histopathological findings are necessary to confirm the
diagnostics. The optimal monitoring of these patients is based on the regular check-ups.
Transvaginal US examinations are much more important than the determination of tumor
associated gene Ca125.
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Figure 1. Borderline tumor of the ovary - histopathological finding